NO20061252L - Doseringsplan for ERBB2 antikreftmidler - Google Patents

Doseringsplan for ERBB2 antikreftmidler

Info

Publication number
NO20061252L
NO20061252L NO20061252A NO20061252A NO20061252L NO 20061252 L NO20061252 L NO 20061252L NO 20061252 A NO20061252 A NO 20061252A NO 20061252 A NO20061252 A NO 20061252A NO 20061252 L NO20061252 L NO 20061252L
Authority
NO
Norway
Prior art keywords
erbb2
mammal
inhibitor
anticancer agents
dosage schedule
Prior art date
Application number
NO20061252A
Other languages
English (en)
Norwegian (no)
Inventor
Richard Damian Connell
Samit Kumar Bhattacharya
James Dale Moyer
Jitesh Pranlal Jani
Dennis Alan Noe
Stefanus Johannes Steyn
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO20061252L publication Critical patent/NO20061252L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20061252A 2003-08-18 2006-03-17 Doseringsplan for ERBB2 antikreftmidler NO20061252L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49591903P 2003-08-18 2003-08-18
PCT/IB2004/002580 WO2005016347A1 (en) 2003-08-18 2004-08-06 Dosing schedule for erbb2 anticancer agents

Publications (1)

Publication Number Publication Date
NO20061252L true NO20061252L (no) 2006-05-16

Family

ID=34193358

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061252A NO20061252L (no) 2003-08-18 2006-03-17 Doseringsplan for ERBB2 antikreftmidler

Country Status (18)

Country Link
US (1) US20050119288A1 (enExample)
EP (1) EP1658080A1 (enExample)
JP (1) JP2007502807A (enExample)
KR (2) KR20080014144A (enExample)
CN (1) CN1838959A (enExample)
AR (1) AR045268A1 (enExample)
AU (1) AU2004264726A1 (enExample)
BR (1) BRPI0413745A (enExample)
CA (1) CA2536140A1 (enExample)
CO (1) CO5670356A2 (enExample)
IL (1) IL173127A0 (enExample)
MX (1) MXPA06001989A (enExample)
NO (1) NO20061252L (enExample)
RU (1) RU2328287C2 (enExample)
SG (1) SG135193A1 (enExample)
TW (1) TW200522966A (enExample)
WO (1) WO2005016347A1 (enExample)
ZA (1) ZA200600517B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1478648E (pt) 2002-02-01 2014-07-15 Ariad Pharma Inc Compostos contendo fósforo e suas utilizações
US8505468B2 (en) * 2002-11-19 2013-08-13 Sharp Kabushiki Kaisha Substrate accommodating tray
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
DK1660090T3 (da) * 2003-08-14 2012-12-17 Array Biopharma Inc Quinazolin-analoger som receptor-tyrosinkinase-inhibitorer
ES2279441T3 (es) 2003-09-19 2007-08-16 Astrazeneca Ab Derivados de quinazolina.
KR20080095915A (ko) 2004-05-06 2008-10-29 워너-램버트 캄파니 엘엘씨 4-페닐아미노-퀴나졸린-6-일-아미드
GB0427131D0 (en) * 2004-12-10 2005-01-12 Glaxosmithkline Biolog Sa Novel combination
JP2008542354A (ja) * 2005-06-03 2008-11-27 ファイザー・プロダクツ・インク 癌治療におけるｅｒｂＢ２阻害剤と他の治療薬の併用
EP1890677A4 (en) * 2005-06-16 2013-01-30 Myriad Genetics Inc PHARMACEUTICAL COMPOSITIONS AND THEIR USE
US20080219977A1 (en) * 2005-07-27 2008-09-11 Isaiah Josh Fidler Combinations Comprising Gemcitabine and Tyrosine Kinase Inhibitors for the Treatment of Pancreatic Cancer
US8945573B2 (en) * 2005-09-08 2015-02-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Targeted identification of immunogenic peptides
WO2007059106A2 (en) * 2005-11-14 2007-05-24 Ariad Gene Therapeutics, Inc. Administration of mntor inhibitor to treat patients with cancer
ATE446294T1 (de) 2005-11-15 2009-11-15 Array Biopharma Inc N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i- rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten
RU2429014C2 (ru) * 2006-03-31 2011-09-20 Массачусетс Инститьют Оф Текнолоджи Лечение опухолей, экспрессирующих мутантные рецепторы egf
KR20080108516A (ko) * 2006-04-05 2008-12-15 노파르티스 아게 암을 치료하기 위한 치료제의 조합물
JP2010509400A (ja) 2006-11-14 2010-03-25 アリアド・ファーマシューティカルズ・インコーポレイテッド 経口処方組成物
NZ580866A (en) * 2007-04-10 2011-02-25 Myriad Pharmaceuticals Inc Method of treating brain cancer
NZ580868A (en) * 2007-04-10 2011-07-29 Myriad Pharmaceuticals Inc Dosages and methods for the treatment of cancer
WO2008124828A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating vascular disruption disorders
EP2144886A4 (en) * 2007-04-10 2012-10-03 Myrexis Inc METHOD OF TREATING MELANOMA
NZ580869A (en) * 2007-04-10 2011-02-25 Myriad Pharmaceuticals Inc Methods for treating cancer
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
PL2171090T3 (pl) * 2007-06-08 2013-09-30 Genentech Inc Markery ekspresji genów odporności guza na leczenie hamujące HER2
WO2009137714A2 (en) * 2008-05-07 2009-11-12 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
WO2010027848A2 (en) * 2008-08-26 2010-03-11 Teva Pharmaceutical Industries Ltd. Forms of lapatinib compounds and processes for the preparation thereof
MY152068A (en) 2009-03-20 2014-08-15 Genentech Inc Bispecific anti-her antibodies
JP6130391B2 (ja) 2011-11-23 2017-05-17 インテリカイン， エルエルシー Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
JP6183471B2 (ja) * 2014-01-31 2017-08-23 凸版印刷株式会社 生体分子解析キット及び生体分子解析方法
US11160871B2 (en) 2015-10-28 2021-11-02 Tarveda Therapeutics, Inc. SSTR-targeted conjugates and particles and formulations thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA932522B (en) * 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
DE69536015D1 (de) * 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
EP1292591B1 (en) * 2000-06-22 2005-02-02 Pfizer Products Inc. Substituted bicyclic derivatives for the treatment of abnormal cell growth
AP2004003058A0 (en) * 2001-12-12 2004-06-30 Pfizer Prod Inc Quinazoline derivatives for the treatment of abnormal cell growth.
PL370858A1 (en) * 2001-12-12 2005-05-30 Pfizer Products Inc. Salt forms of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and method of production
WO2004046101A2 (en) * 2002-11-20 2004-06-03 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as erbb2 and egfr inhibitors
RU2005119172A (ru) * 2002-12-18 2006-01-20 Пфайзер Продактс Инк. (Us) Производные 4-анилинхиназолина для лечения патологического роста клеток

Also Published As

Publication number Publication date
SG135193A1 (en) 2007-09-28
MXPA06001989A (es) 2006-05-17
US20050119288A1 (en) 2005-06-02
RU2328287C2 (ru) 2008-07-10
AU2004264726A1 (en) 2005-02-24
BRPI0413745A (pt) 2006-10-24
RU2006102125A (ru) 2007-09-27
IL173127A0 (en) 2006-06-11
CO5670356A2 (es) 2006-08-31
TW200522966A (en) 2005-07-16
JP2007502807A (ja) 2007-02-15
KR20080014144A (ko) 2008-02-13
WO2005016347A1 (en) 2005-02-24
CA2536140A1 (en) 2005-02-24
CN1838959A (zh) 2006-09-27
EP1658080A1 (en) 2006-05-24
ZA200600517B (en) 2007-02-28
KR20060037447A (ko) 2006-05-03
AR045268A1 (es) 2005-10-19

Similar Documents

Publication Publication Date Title
NO20061252L (no) Doseringsplan for ERBB2 antikreftmidler
ZA202109010B (en) Compounds and methods for the treatment of covid-19
NO20050204L (no) Kombinasjoner av legemidler for behandling av neoplasmer
RU2010133480A (ru) Лечение метастатической стадии рака предстательной железы дегареликсом
NO20092150L (no) Fremgangsmater for behandling av hyperkolesterolemi
AR083957A1 (es) Tratamiento para modular las celulas nk y metodos para tratar malignidad hematologica
TW200500355A (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
WO2010141842A3 (en) Interlaced method for treating cancer or a precancerous condition
MX2021002349A (es) Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario.
BR0314699A (pt) Composto, composição e métodos para o tratamento da dor e para inibição da função vr1 em uma célula
UA81625C2 (ru) Применение ротиготина для трансепикутального лечения синдрома уставших ног
BR0014166A (pt) Método de utilização de inibidores de reabsorção de serotonina seletivo de rápido ataque para tratamento de disfunção sexual
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
TW200639159A (en) Treatment of pain
FI3630177T3 (fi) Hoitoparadigma anti-cd19-vasta-aineen ja venetoklaksin yhdistelmähoidolle
MX2007004955A (es) Metodo de tratar cancer con formulaciones de compeusto de platino a base de lipido administradas intraperitonealmente.
TW200719903A (en) Compositions for the treatment of neoplasms
MX2010002679A (es) Derivados de 4-oxoquinolina deuterados para el tratamiento de la infeccion por el virus de inmunodeficiencia humana.
MX2012005497A (es) Tivozanib y temsirolimus en combinacion.
NO20063320L (no) Anvendelse av gaboxadol for behandling av insomni
MX2023008796A (es) Métodos para el tratamiento del trastorno del habla en niños.
TW200635609A (en) Novel pharmaceutical composition containing at least one dolastatin 10 derivative
MXPA05006378A (es) Compuestos esteroides con actividad anti-tumoral.
WO2025049967A3 (en) Inhibition of pcbp2 to enhance efficacy of immunotherapy
WO2021137935A3 (en) Novel superebastine against therapy resistant prostate cancer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application